Document is current
Any future updates will be listed below
-
Authors
Fonseca, Rafael
Diels, Joris
Ghilotti, Francesca
Mendes, João
Van Hoorenbeeck, Sandra
Lee, Seina
Schecter, Jordan M.
Lendvai, Nikoletta
Patel, Nitin
Triguero, Ana
Alsdorf, Winfried
van de Donk, Niels W. C. J.
Ursi, Margherita
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04181827 at ClinicalTrials.govDocuments that mention this clinical trial
First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.
https://doi.org/10.1200/jco.2023.41.17_suppl.lba106
Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician’s Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma
https://doi.org/10.1007/s12325-025-03308-2
Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting
https://doi.org/10.1007/s12325-025-03278-5
Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis.
https://doi.org/10.1200/jco.2024.42.16_suppl.7504
-
Funding
Funding for this research was provided by:
Johnson & Johnson
Legend Biotech USA Inc.
Paula and Rodger Riney Foundation
NCI (NCI U01CA271410)
- License Information
-
More Information
Article History
Received: 30 April 2025
Accepted: 4 June 2025
First Online: 4 July 2025
Declarations
:
: Rafael Fonseca has a consulting or advisory role with AbbVie, Adaptive, Amgen, Apple, Arduro Biotech, BMS/Celgene, Bayer, GSK, Gilead, Janssen, Juno Therapeutics, Karyopharm, Kite, Merck Sharp & Dohme, Oncopeptides, Oncotracker, Pfizer, Pharmacyclics, RA Capital, Regeneron, Sanofi and Takeda; holds a patent for fluorescence in situ hybridization in multiple myeloma; sits on the board of directors of Antengene; and received honoraria from AbbVie, Aduro Biotech, Amgen, Bayer, Bristol Myers Squibb, Celgene, Janssen, Juno Therapeutics, Kite, Merck, OncoTracker, Sanofi, Sharp & Dohme and Takeda. Joris Diels, Francesca Ghilotti, João Mendes, Sandra Van Hoorenbeeck, Seina Lee, Jordan M Schecter and Nikoletta Lendvai are employed by Johnson & Johnson and may own stock in Johnson & Johnson. Nitin Patel is employed by Legend; and has stock and other ownership interests in Legend Biotech. Ana Triguero and Margherita Ursi declare that they have no competing interests. Winfried Alsdorf has a consulting or advisory role with Immatics and Johnson & Johnson; received honoraria from Astellas, AstraZeneca, GSK and Johnson & Johnson; received research funding (received by institution) from Affimed and Biontech; and received travel, accommodations and/or expenses from Biontech, Immatics and Johnson & Johnson. Niels WCJ van de Donk has a consulting or advisory role with Adaptive Biotechnologies, Abbvie, Amgen, Celgene, Bayer, Bristol Myers Squibb, Galapagos, Johnson & Johnson, Kite Pharma, Merck, Novartis, Pfizer, Roche, Sanofi, Servier and Takeda; and received research funding from Amgen, Bristol Myers Squibb, Celgene, Cellectis, Johnson & Johnson and Novartis.
: The trials were conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation guidelines for Good Clinical Practice. All patients provided written informed consent. The independent ethics committee or institutional review board at each site approved the trial protocol.
